Abstract

Truncated dominant negative forms of CEBPB and CEBPD, and cell-penetrating forms thereof are described. Methods for using the truncated dominant negative forms of CEBPB and CEBPD proteins, and cell-penetrating forms thereof, for decreasing viability of neoplastic cells and treating cancer in a subject are also described.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

Apparatus and methods are disclosed to assess tissue properties, especially those of lung tissues. By measuring impedance in response to electrical stimulation, a variety of properties can be deduced including spatial location of damaged tissue, presence of epithelial cells and function of diseased tissue. To these ends, a probe (10) with electrodes (12, 14, 16, 18) connected to an impedance analyzer (20) was developed for assessing tissue (22) function. By applying voltages and/or currents, different information can be determined. In another embodiment, such a probe can be used for electroporation to evaluate the location of genetic molecules (e.g., RNA, DNA, or gene-editing machinery) and/or encourage their transport across different layers of tissue (FIG. 11).

IPC Classes  ?

• A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/08 - Measuring devices for evaluating the respiratory organs

Abstract

The method of generating multipotent stem cells is a method for producing and/or expanding multipotent stem cells by delivering at least one reprogramming protein into somatic cells. The at least one reprogramming protein includes a Master Regulator (MR) protein, which may be BAZ2B, ZBTB20, ZMAT1, CNOT8, KLF12, DMTF1, HBP1, or FLI1. The bromodomain protein BAZ2B, in particular, was identified by first generating bi-species heterokaryons by fusing Tcf7l1−/− murine embryonic stem cells (ESCs) with human B-cell lymphocytes. Reprogramming of the B-cell nuclei to a multipotent state was tracked by human mRNA transcript profiling at multiple timepoints. Interrogation of a human B-cell regulatory network with gene expression signatures collected from such reprogramming time series identified eight candidate Master Regulator proteins, which were validated in human cord blood-derived hematopoietic progenitor and lineage-committed cells.

IPC Classes  ?

• C12N 5/0789 - Stem cells; Multipotent progenitor cells
• C12N 15/86 - Viral vectors

Abstract

Described herein is a fusion polypeptide comprising a sarbecovirus binding moiety linked to a nanocage monomer or subunit thereof, wherein the sarbecovirus binding moiety is capable of binding to SARS-CoV-2 and at least one sarbecovirus other than SARS-CoV-2. Also described are methods for treating and/or preventing sarbecovirus infection and/or a sarbecovirus-associated condition.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus

Abstract

Disclosed are systems, methods, and other implementations, including a method for monitoring and managing battery performance that includes deriving a representation of diffusion overpotential behavior for a lithium-ion battery according to a discrete-time state-space approximation of a convolution-defined diffusion (CDD) model for the lithium-ion battery, and determining behavior of the lithium-ion battery according to the discrete-time state-space approximation of the convolution-defined diffusion (CDD) model for the lithium-ion battery.

IPC Classes  ?

• G01R 31/388 - Determining ampere-hour charge capacity or SoC involving voltage measurements
• G01R 31/36 - Arrangements for testing, measuring or monitoring the electrical condition of accumulators or electric batteries, e.g. capacity or state of charge [SoC]
• G01R 31/392 - Determining battery ageing or deterioration, e.g. state of health
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells

Abstract

Disclosed are systems, methods, and other implementations, including a method for managing battery performance that includes measuring voltage response data for a lithium-ion battery in response to a current pulse perturbation injected into the lithium-ion battery, and determining in real-time, based on the measured voltage response data, resultant degradation data representative of estimated physical degradation of the lithium-ion battery.

IPC Classes  ?

• G01R 31/392 - Determining battery ageing or deterioration, e.g. state of health
• G01R 31/367 - Software therefor, e.g. for battery testing using modelling or look-up tables
• G01R 31/3835 - Arrangements for monitoring battery or accumulator variables, e.g. SoC involving only voltage measurements

Abstract

The present disclosure provides systems, compositions, and methods for nucleic acid modification. More particularly, the present disclosure provides systems comprising a TnpA protein, a TnpB protein, an IscB protein, or a combination thereof, and methods using thereof.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• A61K 39/02 - Bacterial antigens

Abstract

A dual function material is provided that captures carbon dioxide from ambient air, i.e., direct air capture, and converts the CO2 to a desired product such as methane. The material includes a high surface area carrier such as Al2O3 upon which catalysts and alkaline adsorbents are positioned proximate each other. In the presence of reactive gas such as hydrogen, the catalysts reduce the adjacent adsorbents to generate additional active sites and enhance the amount of CO2 captured by the material. Once the material becomes saturated with CO2, hydrogen is reintroduced to reduce the catalyst, such as ruthenium, at which time the adsorbed CO2 can migrate from the adsorbent to the catalyst for catalytic conversion to methane. The materials can be employed in isothermal, cyclic reactor systems where target species are bound and then desorbed to reactivate the material, e.g., bind more target species for desorption and/or conversion to additional product.

IPC Classes  ?

• B01D 53/04 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography with stationary adsorbents
• B01J 20/04 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• B01J 23/46 - Ruthenium, rhodium, osmium or iridium
• B01J 37/08 - Heat treatment
• C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen

Abstract

Disclosed are novel heterobifunctional compounds that induce p53Y220C acetylation, and methods for use of such compounds in the treatment of p53Y220C-mediated diseases.

IPC Classes  ?

• C07D 487/16 - Peri-condensed systems
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61P 35/00 - Antineoplastic agents

Abstract

Method for unified networking for a device in heterogeneous mobile environments includes maintaining and monitoring active network interfaces, managing the location of the device, managing network access security, enabling disruption tolerance support for applications, enabling service sharing and session mobility, managing system parameters for one or more active application sessions, managing storage functionality in one or more memory devices, and maintaining a mapping for one or more flows corresponding to the one or more active application sessions, maintaining one or more policies, and performing flow control decisions based upon the policies using a policy engine. The method can also include monitoring for network events, evaluating whether to perform a handover based upon policies, and providing seamless secure handovers in a heterogeneous mobile environment. A device, non-transitory computer-readable medium, and a system for unified networking are also provided.

IPC Classes  ?

• H04W 76/16 - Setup of multiple wireless link connections involving different core network technologies, e.g. a packet-switched [PS] bearer in combination with a circuit-switched [CS] bearer
• H04L 43/08 - Monitoring or testing based on specific metrics, e.g. QoS, energy consumption or environmental parameters
• H04L 47/193 - Flow control; Congestion control at layers above the network layer at the transport layer, e.g. TCP related
• H04L 47/20 - Traffic policing
• H04L 61/103 - Mapping addresses of different types across network layers, e.g. resolution of network layer into physical layer addresses or address resolution protocol [ARP]
• H04L 61/4511 - Network directories; Name-to-address mapping using standardised directory access protocols using domain name system [DNS]
• H04L 61/5084 - Providing for device mobility
• H04L 69/321 - Interlayer communication protocols or service data unit [SDU] definitions; Interfaces between layers
• H04W 28/02 - Traffic management, e.g. flow control or congestion control
• H04W 36/00 - Handoff or reselecting arrangements
• H04W 36/16 - Performing reselection for specific purposes

Abstract

Disclosed herein are methods of diagnosing a disease or condition associated with abnormal platelet activation in a subject. Also disclosed herein are methods for assessing the propensity of donor platelets to release an uptaken fluorescent false neurotransmitter (FFN).

IPC Classes  ?

• G01N 21/64 - Fluorescence; Phosphorescence
• C07D 221/08 - Aza-anthracenes
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

Compositions, and methods of treating a subject using the compositions, for treating obesity, reducing body weight, treating chronic inflammation associated with obesity, reducing focal adiposity, and improving metabolism. The compositions include a complex comprising cationic PAMAM generation 3 (P-G3) and human serum albumin (HSA). The complex may be a cfRNA or cfDNA scavenger.

IPC Classes  ?

• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 31/74 - Synthetic polymeric materials
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 3/04 - Anorexiants; Antiobesity agents
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants

Abstract

Methods of crosslinking collagenous tissue include contacting the tissue with a sugar; and illuminating the tissue with any one or more of UV-A light or a femtosecond laser, the illuminating being performed under conditions sufficient to give rise to crosslinking within the tissue is a method of treating a tissue of a cornea. Method of treating a tissue of a cornea include restricting oxygen replenishment of the tissue; contacting the tissue with a sugar; and illuminating the tissue with at least one of UV-A light or a femtosecond laser, the illuminating being performed under conditions sufficient to give rise to crosslinking within the tissue. Methods of treating a collagenous tissue include contacting the tissue with a sugar; and illuminating the tissue with any one or more of UV-A light or a femtosecond laser, the illuminating being performed under conditions sufficient to give rise to crosslinking within the tissue.

IPC Classes  ?

• A61K 31/70 - Carbohydrates; Sugars; Derivatives thereof
• A61N 5/06 - Radiation therapy using light

Abstract

Exemplary embodiments of the present disclosure provides biomaterials, systems, and methods that utilize upconversion biomaterials to stimulate optogenetic cells in three-dimensional settings. Provided is a biomaterial including chromophores capable of converting low-energy light to high-energy light embedded in biocompatible materials. This technology enables more selective stimulation of optogenetic cells in three-dimensional scaffolds and has the potential to provide critical insights into cell function and disease.

IPC Classes  ?

• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
• C09K 11/02 - Use of particular materials as binders, particle coatings or suspension media therefor
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

Described herein is a therapeutic method that specifically addresses tumor-infiltrated regulatory T cells (Tregs) with minimal impact on the peripheral Tregs.

IPC Classes  ?

• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
• A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates to delta-2-tubulin and its use as a biomarker for determining if a subject is at risk of developing peripheral neuropathy or if a subject has developed peripheral neuropathy. The present disclosure further relates to methods for the treatment of peripheral neuropathy in a subject and assays for identifying compounds that can be used to treat and/or prevent peripheral neuropathy.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61K 31/69 - Boron compounds
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer

Abstract

inter aliainter alia, compounds to modulate GPX4 activity. Also provided are pharmaceutical compositions containing such compounds. Further provided are methods for treating or ameliorating the effects of a cancer in a subject, methods of modulating GPX activity in a subject, methods of inducing ferroptosis in a cell, and methods for treating or ameliorating the effects of a cancer in a subject using the compounds or composition in combination with other therapeutic agents.

Abstract

The present invention provides a compound having the structure: The present invention provides a compound having the structure: wherein R1 is —(C2-C12 alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl); R2 is H, halogen, —NO2, —CN, —CF3, —CF2H, —CH2OCH3, —CF2CH3, —CF2OCH3, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), -(heterocycle), -(heterocycloalkyl), -(aryl), -(heteroaryl), -(hydroxyalkyl), -(haloalkyl), -(alkylaryl), —OH, —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(haloalkyl), —O-(aryl), —O-(heteroaryl), —OCF3, SH, —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —N-(alkyl)2, NH-(aryl), —NH-(heteroaryl), —CO2H, —CO2-(alkyl), —C(O)—NH2, —C(O)—NH-(alkyl), —C(O)—NH-(aryl), —SO2CH3 or —Si(CH3) 3; R3 is —OCH3, —OCH2CH3, —F or —Cl; and R4 is —OCH3, —OCH2CH3 or —SCH3; wherein when R1 is —CH2CH3, R3 is —OCH3, and R4 is —OCH3, then R2 is other than H, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH2CH2CH3, —CH2OH, —CH(OH) CH3, —OH, —OCH2CH3, —OCH2CH2CH3, —OCH(CH3)2, —SCH3, —SCH2CH3, —SCH2CH2CH3, —NO2, —NH2, —F, —Cl, —Br or —I, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• C07C 217/60 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
• C07C 255/59 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
• C07C 317/32 - Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07C 323/32 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
• C07D 305/06 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

1212223223232332222223333 3234323312333432323223322223232322332323223222, -F, -Cl, -Br or -I, or a pharmaceutically acceptable salt thereto.

Abstract

Compositions and methods for treating insulin resistance, reducing blood glucose level, increasing insulin tolerance, and treating diabetes. The methods include administering the composition to a subject. The subject may express insulin receptor with site-1 binding-deficient mutations or insulin-desensitized insulin receptor. The composition includes a synthetic peptide of 18-35 amino acid residues in length. The composition may include insulin or an analog thereof. The synthetic peptide has a linker region and a component 2 region. The synthetic peptide may also have a component 1 region. A method of activating PI3K-AKT pathway without activating MAPK pathway in a cell includes administering the synthetic peptide to the cell. Uses for the synthetic peptide include the treatment of insulin resistance, the reduction of blood glucose level, increasing insulin tolerance, treating diabetes, and the manufacture of a medicament for these purposes.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

The present disclosure relates to the methods and systems for multimodal profiling. The method can include stabilizing a target, performing a tagmentation on the target using an agent, and generating a library using a reverse transcriptase enzyme. The agent can include a Tn5 transposome complex, a Tn5 transposase reagent, or a combination thereof, and the Tn5 transposome complex or the Tn5 transposase reagent can be loaded with an adapter. The reverse transcriptase enzyme can be configured to transcribe DNA from both a DNA template and an RNA template and perform a terminal transferase activity by template switching and an introduction of an adapter sequence into a cDNA and a transposed chromatin of the target.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present disclosure provides, inter alia, chimeric nanobody compositions that selectively modulate the function of a target protein within a defined population of cells. Also provided are methods for treating diseases such as ion channelopathies.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes

Abstract

The present disclosure provides, inter alia, compositions and methods for treating or ameliorating the effect of a disorder such as, e.g., anxiety or depression in a subject, with less or no off- and/or on-target side effects. Also provided are methods for treating such disorder in a pregnant woman.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/51 - Nanocapsules
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Systems and methods for generating one or more single crystal monolayers from two-dimensional van der Waals crystals are disclosed herein. Example methods include providing a bulk material including a plurality of van der Waals crystal layers, and exfoliating one or more single crystal monolayers of van der Waals crystal from the bulk material by applying a flexible and flat metal tape to a surface of the bulk material. In certain embodiments, the one or more single crystal monolayers can be assembled into an artificial lattice. The present disclosure also provides techniques for manufacturing flexible and flat metal tape for generating one or more single crystal monolayers from two-dimensional van der Waals crystals. The present disclosure also provides compositions for creating a macroscopic artificial lattice. In certain embodiments, the composition can include two or more macroscopic single crystal monolayers adapted from a bulk van der Waals crystal, where the single crystal monolayers are configured for assembly into an artificial lattice based on one or more properties.

IPC Classes  ?

• C30B 33/00 - After-treatment of single crystals or homogeneous polycrystalline material with defined structure
• B32B 7/02 - Physical, chemical or physicochemical properties
• B32B 18/00 - Layered products essentially comprising ceramics, e.g. refractory products
• B32B 37/00 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding
• B32B 37/18 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the properties of the layers with all layers existing as coherent layers before laminating involving the assembly of discrete sheets or panels only
• B32B 43/00 - Operations specially adapted for layered products and not otherwise provided for, e.g. repairing; Apparatus therefor
• C23C 14/16 - Metallic material, boron or silicon on metallic substrates or on substrates of boron or silicon
• C23C 14/30 - Vacuum evaporation by wave energy or particle radiation by electron bombardment
• C30B 29/46 - Sulfur-, selenium- or tellurium-containing compounds
• C30B 29/68 - Crystals with laminate structure, e.g. "superlattices"

Abstract

Natural antibodies are an integral part of innate humoral immunity yet their development and polyreactive nature are still enigmatic. Here it is shown that characteristic monoclonal natural antibodies recognize common chemical moieties or adducts, supporting the view that polyreactive antibodies may often correspond to anti-adduct antibodies. Moreover, the development of IgM and IgG to 81 ubiquitous adducts from birth to old age was examined. Newborn IgM only reacted to a limited number of consensus determinants. This highly restricted neonatal repertoire abruptly diversified around 6 months of age through the development of antibodies to environmental antigens as well as age-driven epigenetic modifications. In contrast, the IgG repertoire was diverse across the entire lifespan. The studies set forth reveal an unrecognized but significant component of humoral immunity directed to common adducts.

IPC Classes  ?

• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The subject matter described here relates to bispecific antibodies capable of modulating T-cell activity, wherein the two arms of the bispecific antibody are against CD3 and SLAMF6, against CD45 and SLAMF6, or against CD43 and SLAMF6.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Abstract

A structured material is provided that includes a substrate and a porous structured polymer layer disposed thereon. The porous structured polymer layer includes a plurality of voids, and has a high hemispherical reflectance a high a hemispherical thermal emittance. The structured material is thus particularly advantageous for cool-roof coatings, enabling surfaces coated by the material to stay cool, even under strong sunlight. The material can be produced via structuring of polymers in a mixture including a solvent and a non-solvent. Sequential evaporation of the solvent and the non-solvent provide a polymer layer with the plurality of voids.

IPC Classes  ?

• G02B 26/00 - Optical devices or arrangements for the control of light using movable or deformable optical elements
• C08J 9/28 - Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
• C08K 5/00 - Use of organic ingredients
• C09D 5/33 - Radiation-reflecting paints
• E04D 7/00 - Roof covering by sealing masses applied in situ; Gravelling of flat roofs
• E04D 13/00 - Special arrangements or devices in connection with roof coverings; Roof drainage
• E04F 13/08 - Coverings or linings, e.g. for walls or ceilings composed of covering or lining elements; Sub-structures therefor; Fastening means therefor composed of a plurality of similar covering or lining elements
• E06B 9/24 - Screens or other constructions affording protection against light, especially against sunshine; Similar screens for privacy or appearance
• G02B 1/14 - Protective coatings, e.g. hard coatings
• G02B 5/20 - Filters

Abstract

A process, apparatus, and cyclopropenimine (CPI) material for generating metal carbonates are disclosed. Generating the metal carbonates comprises reacting carbon dioxide (CO2) with CPI. Generating the metal carbonates also comprises forming a reaction mixture comprising water, metal cations, and a product of the reacting.

IPC Classes  ?

• C07C 251/18 - Compounds containing nitrogen atoms doubly- bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of rings other than six-membered aromatic rings
• C01D 7/14 - Preparation of sesquicarbonates
• C01F 5/24 - Magnesium carbonates
• C01F 11/18 - Carbonates

Abstract

Implementations present convolutional neural network based spectral registration (CNN-SR) techniques that achieve efficient and accurate simultaneous frequency-and-phase correction (FPC) of magnetic resonance spectroscopy (MRS) data. Magnetic resonance spectroscopy research and clinical applications have provided invaluable information on the metabolic state of the brain. However, the data collection and analysis can be improved. For example, MRS data often undergoes correction after the data is collected, such as frequency correction and/or phase correction. Implementations provide CNN-SR techniques to correct frequency and phase offset at the same time (e.g., simultaneously). The CNN-SR techniques leverages properties of a CNN that exploit spatial and temporal invariance in recognition of features, such as the overall shape of the signal and its peaks. Some embodiments perform model training in multiple phase and implement different training techniques (e.g., supervised training, unsupervised training, etc.) using different data sets.

IPC Classes  ?

• G01R 33/485 - NMR imaging systems with selection of signal or spectra from particular regions of the volume, e.g. in vivo spectroscopy based on chemical shift information
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• G01R 23/16 - Spectrum analysis; Fourier analysis

Abstract

The subject matter described herein relates to a method of treating or preventing prostate cancer in a subject with administration of a composition comprising a Nuclear Receptor Binding Set Domain Protein 2 (NSD2) inhibitor.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Abstract

This application describes Swept, Confocally-Aligned Planar Excitation (SCAPE) microscopy systems that incorporate a gradient index (GRIN) lens to relay images from their distal tip to their proximal tip so that 3D images of deep tissue can be captured, without undue loss of light. A zero working distance feature can be designed into the third objective to ensure that the light that exits the second objective in the SCAPE system is not lost. Alternatively, a tapered fiber bundle may be positioned between the second objective and the third objective in the SCAPE system to ensure that the light that exits the second objective is not lost. As yet another alternative, direct detection at the intermediate image plane without using a third objective can ensure that the light that exits the second objective in the SCAPE system is not lost.

IPC Classes  ?

• G02B 21/00 - Microscopes
• G02B 3/00 - Simple or compound lenses
• G02B 21/33 - Immersion oils
• G02B 21/36 - Microscopes arranged for photographic purposes or projection purposes

Abstract

Anti-Fn amyloid-like FadA antibodies and compositions are provided and methods of treating cancers, including pancreatic and colorectal, and periodontal diseases. Methods include preventing, reducing development, or treating disease in a subject in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent which inhibits or blocks an amyloid-like FadA secreted from Fusobacterium nucleatum (Fn).

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

A process, composition, and apparatus for carbon dioxide (CO2) conversion are disclosed. The CO2 conversion comprises reacting CO2 with a cyclopropenimine (CPI) to activate the CO2 and transferring the activated CO2 to generate a product of the transferring. The transferring also generates a conjugate acid of the CPI. The process further comprises regenerating the CPI from the conjugate acid.

IPC Classes  ?

• B01J 20/26 - Synthetic macromolecular compounds
• B01D 53/62 - Carbon oxides
• B01D 53/78 - Liquid phase processes with gas-liquid contact
• B01D 53/96 - Regeneration, reactivation or recycling of reactants
• B01J 20/34 - Regenerating or reactivating

Abstract

A photo-switchable nanocrystal can be provided which can include solely one or more inorganic elements. Further, a method for synthesizing photo-switchable nanocrystal can be provided which can utilize solely inorganic elements. For example, the fully inorganic element(s) can comprise lanthanide ion (Ln3+)-based phosphors. Further, the nanocrystal can be photostable and/or does not photodegrade with light excitation cycles.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61N 5/06 - Radiation therapy using light
• C01F 17/36 - Compounds containing rare earth metals and at least one element other than a rare earth metal, oxygen or hydrogen, e.g. La4S3Br6 halogen being the only anion, e.g. NaYF4
• C09K 11/77 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals
• G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics

Abstract

Compositions and methods for identifying an RNA regulatory element on a target gene, and for treating a disease with a disease-associated genetic variant. The compositions include a vector for expressing the target gene and a first fluorescence signal that may be a green fluorescent protein (GFP), and a second fluorescence signal wherein the nucleic acid sequence encoding the target gene is between the first fluorescent signal and the second fluorescent signal; a vector for expressing enzymatically dead Cas13 (dCas13) and a third fluorescence signal; and a vector for expressing a guide RNA (gRNA), wherein the nucleotide sequence of the gRNA is complementary to regions of the target gene comprising RNA regulatory elements.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

Disclosed herein are methods for regulating an immune response using selective activation of neurons in the caudal nucleus of the solitary tract.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo

Abstract

A process, apparatus, and material for generating polymers are disclosed. Generating the polymers comprises reacting carbon dioxide (CO2) with a cyclopropenimine (CPI). Generating the polymers further comprises reacting monomers with a product of the reaction between the CPI and the CO2.

IPC Classes  ?

• C08G 64/32 - General preparatory processes using carbon dioxide
• C08G 64/16 - Aliphatic-aromatic or araliphatic polycarbonates
• C08G 71/04 - Polyurethanes

Abstract

A method of treating cancer in a subject using a kinome and/or phosphorylome analysis approach, a SPHINKS computational analysis, or a combination thereof to target master kinases driving the cancer state.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation

Abstract

The present disclosure provides compositions and methods of treating or preventing neurodegenerative diseases, including tau-related diseases or tauopathies. A variant or mutant of a heat shock protein, such as an Hsp70 family member protein, may be used in the present method. Alternatively, a modulator of a heat shock protein may be used.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Goods & Services

MEDICAL SERVICES

Abstract

The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Circuit for wake-up receivers are provide. In some embodiments, the wake-up receivers include self-mixers that receive a gate bias voltage. Some of the self-mixers are single ended and some are differential. In some embodiments, the wake-up receivers include a matching network that is connected to the input of the self-mixer. In some embodiments, the wake-up receivers include a low frequency path connected to the output of the self-mixer. In some embodiments, the wake-up receivers include a high frequency path connected to the output of the self-mixer. In some embodiments, the wake-up receivers are configured to receive an encoded bit stream. In some embodiments, the wake-up receivers are configured to wake-up another receiver.

IPC Classes  ?

• H04L 27/06 - Demodulator circuits; Receiver circuits
• H03K 19/0185 - Coupling arrangements; Interface arrangements using field-effect transistors only
• H03K 19/17788 - Structural details for adapting physical parameters for input/output [I/O] voltages
• H04L 27/26 - Systems using multi-frequency codes

Abstract

in vitroFaecalibacterium rodentiumErysipelotrichaceae Erysipelotrichaceae family in the subject may provide a similar result. ILC3 or IL-22 blockade (alone or combined with Th17 cell administration or induction if not already present in the subject), may further provide a similar result, protecting against metabolic disease.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 3/04 - Anorexiants; Antiobesity agents

Abstract

Rehabilitation or ambulation assistance can be provided to a user by sensing at least one first pressure beneath the user's right foot, sensing at least one second pressure beneath the user's left foot, and predicting the user's gait based on the sensed at least one first pressure and the sensed at least one second pressure. A plurality of motors are energized at a plurality of times that are synchronized with phases of the user's gait so that the plurality of motors pull on respective cables at respective times in a coordinated sequence. Each of the cables has a first end affixed to a pelvic belt or harness that is shaped and dimensioned to fit securely on the user's pelvis, and the timing of the energizing is based on the gait predictions.

IPC Classes  ?

• A61H 3/04 - Wheeled walking aids for patients or disabled persons
• A61H 1/02 - Stretching or bending apparatus for exercising

Abstract

A copper concentrate such as chalcopyrite is contacted with an aqueous solution includes acids and a reducing agent, such as vanadium (II) ions, chromium (II) ions, or tungstozincic acid (H6ZnW12O40). The aqueous solution reduces the copper in the copper concentrate, which can then dissolve into the solution for recovery therefrom, or precipitate out of solution as copper compounds or elemental copper for recovery in as a solid phase product. The solid phase product can then be isolated, dissolved, and further electrowinned to recover a copper product from the copper concentrate. Oxidized reducing agent can be recovered in an electrochemical device with ferrous iron reactants. Hydrometallurgical routes to convert copper concentrates to copper are potentially less expensive and less polluting than current pyrometallurgical processing and an advantageous response to environmental and economic pressures for increased copper production.

IPC Classes  ?

• C25C 1/12 - Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper

Abstract

The subject matter disclosed herein relates to a method of treating glioblastoma (GBM) in a subject in need thereof, the method comprising determining one or more GBM subtypes in a GBM sample via a pathway-based classifier approach and administering to the subject a pharmaceutically effective amount of an agent capable of modifying the activity of the biological pathways associated with the one or more GMB subtypes.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

In various aspects and embodiments of the disclosure, the invention provides pharmaceutical compositions and methods for protecting against brain injury associated with Hypoxic-Ischemic Encephalopathy (HIE). The compositions and methods employ omega-3 fatty acid (n-3 FA) diglyceride (DG) and/or triglyceride (TG) emulsions, which may be used alone or in combination with therapeutic Hypothermia (HT).

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 9/107 - Emulsions
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Abstract

A method of detecting or diagnosing squamous cancers in a sample from a subject, including isolating extracellular vesicles from the sample, wherein the extracellular vesicles are cancer specific.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 1/40 - Concentrating samples

Abstract

The present invention provides, inter alia, methods for treating or ameliorating the effects of a disorder, such as schizophrenia or bipolar disorder, by increasing or decreasing proline levels. Further provided are methods of predicting and monitoring the clinical response in a patient, and diagnostic systems for identifying a patient likely to benefit from proline modulation.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61P 25/18 - Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/506 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relates to methods for regulating cholesterol efflux in retinal pigment epithelium cells and treating or preventing a neurodegenerative disease or disorder (e.g., macular degeneration).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 15/86 - Viral vectors
• A61K 38/18 - Growth factors; Growth regulators

Abstract

Methods for conversion of a broad range of amines to their 15N isotopic counterparts and the compounds produced thereby.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds

Abstract

Devices and methods for joining a first and second tissue in a patient are disclosed that include a base with a plurality of recurved tines oriented to a tine axis and extending from a first surface of the base. The tines provide unidirectional traction of the first tissue along the tine axis toward the first surface. The first tissue is secured to the first surface of the device at the plurality of recurved tines and the second tissue is secured to the device at a second surface opposite the first surface to join the first and second tissues.

IPC Classes  ?

• A61F 2/08 - Muscles; Tendons; Ligaments
• A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

Abstract

Exemplary system, method and computer-accessible medium can be provided to monitor electroencephalography (EEG) data from the patient during an emergence from a general anesthesia previously provided to the patient, and predicting neurocognitive impairment based on a slope of EEG power. The neurocognitive impairment predicted can be delirium or it may be a predictor of long-term impairment such as Alzheimers. Further, the system and method can be used to direct a medical intervention based on the preditcted neurocognitive impairment.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/291 - Bioelectric electrodes therefor specially adapted for particular uses for electroencephalography [EEG]
• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS

Goods & Services

Cufflinks, watches, lanyards for holding keys, key rings, lapel pins, tie bars, necklaces [jewelry], pendants, bracelets, money clips, rings being jewelry, jewelry charms, jewelry rings Lanyards for name badge holders, pens, padfolios, paperweights, stickers, gift bags, decals, stationery-type portfolios, printed paper signs Tote bags, wallets, not of precious metal, wallets, made of precious metal, clutches, credit card cases, fanny packs Drinkware, tumblers for use as drinking glasses Sports caps and hats, bucket hats, baseball caps and hats, cap visors, t-shirts, sweatshirts, polo shirts, shorts, sweatpants, socks, hoodies, pullovers, tank tops, children's and infant's apparel, namely, jumper coveralls, overall sleepwear, pajamas, rompers and one-piece garments, sandals, outer vests, outer jackets, flannel pants, underwear

Goods & Services

Jewelry rings, jewelry charms, watches Drinkware, tumblers for use as drinking glasses

Goods & Services

Key rings Drinkware, tumblers for use as drinking glasses

Goods & Services

Watches, key rings, rings being jewelry, cuff links, money clips, necklaces [jewelry], pendants, bracelets, jewelry charms Paperweights, desktop business card holders, gift bags, decals, printed paper signs, bookends, padfolios Wallets, not of precious metal Drinkware, tumblers for use as drinking glasses

Goods & Services

Cufflinks, watches, lanyards for holding keys, key rings, lapel pins, tie bars, necklaces [jewelry], pendants, bracelets, Money clips, rings being jewelry, jewelry charms, jewelry rings Lanyards for name badge holders, pens, padfolios, paperweights, stickers, gift bags, decals, stationery-type portfolios, printed paper signs, bookends Tote bags, wallets, not of precious metal, wallets, made of precious metal, clutches, credit card cases, fanny packs Drinkware, tumblers for use as drinking glasses

Abstract

The present invention relates to methods and compositions for using plasma Indian hedgehog (IHH) as a biomarker for diagnosing, and as a therapeutic target for treating, liver conditions including non-alcoholic steatohepatitis (NASH).

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

The present disclosure provides for systems and methods for modifying the epigenome of cells.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 5/0793 - Neurons
• A61K 35/30 - Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

A quantitative gait training and/or analysis system employs instrumented footwear and an independent processing module. The instrumented footwear may have sensors that permit the extraction of gait kinematics in real time and provide feedback from it. Embodiments employing calibration-based estimation of kinematic gait parameters are described. An artificial neural network identifies gait stance phases in real-time.

IPC Classes  ?

• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen, e.g., CD33 or EMR2, and a population of hematopoietic cells that are altered in the expression of the lineage-specific cell-surface antigen, e.g., CD33 or EMR2, for immunotherapy of hematological malignancies. Also disclosed herein are methods of administering an agent targeting more than one lineage-specific cell-surface antigen, and a population of hematopoietic cells that are altered in the expression of more than one lineage-specific cell-surface antigen, for immunotherapy of hematological malignancies. Cells comprising mutations in CD33, or EMR2, or more than one lineage-specific cell-surface antigen are also provided, as are methods of producing such cells using CRISPR-based base editor systems.

IPC Classes  ?

• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 5/0775 - Mesenchymal stem cells; Adipose-tissue derived stem cells
• C12N 9/22 - Ribonucleases

Abstract

Provided herein are methods and compositions related to the use of human monocyte-derived microglia-like (MDMi) cells. In some embodiments, the methods and compositions provided herein relate to the use of MDMi cells to assess the effect of a clinical intervention on a human subject (e.g., a subject with a neurodegenerative disorder). In some embodiments, the methods and compositions provided herein relate to the use of MDMi cells to stratify human subjects into subgroup populations (e.g., populations that are likely to respond to a clinical intervention or are unlikely to respond to a clinical intervention). In some embodiments, the methods and compositions provided herein relate to the use of MDMi cells to identify candidate neurodegenerative disease biomarkers. In certain embodiments, the methods and compositions provided herein relate to the use of MDMi cells to screen potential therapeutic agents to identify candidate agents for the treatment of a neurodegenerative disease.

IPC Classes  ?

• C12N 5/079 - Neural cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

Methods for preventing, reducing development of, or treating a peripheral neuropathy in a subject is provided, including taxane-induced peripheral neuropathies, by administration of mesencephalic astrocyte-derived neurotrophic factor MANF or nucleic acids encoding MANF are provided. Methods of treating extant peripheral neuropathies, peripheral reducing taxane-induced macrophage activation, and neuropathy-associated peripheral pain are provided.

IPC Classes  ?

• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Goods & Services

EDUCATIONAL SERVICES, NAMELY, PROVIDING COURSES OF INSTRUCTION AT THE UNIVERSITY LEVEL

Goods & Services

EDUCATIONAL SERVICES, NAMELY, PROVIDING COURSES OF INSTRUCTION AT THE UNIVERSITY LEVEL

Goods & Services

EDUCATIONAL SERVICES, NAMELY, PROVIDING COURSES OF INSTRUCTION AT THE UNIVERSITY LEVEL

Goods & Services

EDUCATIONAL SERVICES, NAMELY, PROVIDING COURSES OF INSTRUCTION AT THE UNIVERSITY LEVEL

Abstract

Exemplary method and configuration for a frequency conversion can be provided. For example, such method and configuration can use at least one transition metal dichalcogenide (TDM) crystal (which can include one or more MoS2 crystals, which can be stacked). For example, it is possible to providing at least one radiation to the at least one TDM crystal so as to generate a resultant radiation. Resultant information can be generated by measuring difference frequency and a second harmonic generation (SHG) from the resultant radiation provided from the TDM crystal. The frequency conversion can be obtained or achieved by providing a measurement of a SHG coherence length based on the resultant information.

IPC Classes  ?

• G02F 1/355 - Non-linear optics characterised by the materials used
• G02F 1/35 - Non-linear optics

Abstract

Mechanisms for defending a computing system from attack are provided. The mechanisms include: maintaining a round counter that tracks a round number for a local host; determining a location in a graph for each of a plurality of hosts including the local host; determining monitor hosts of the plurality of hosts that are monitoring the local host; determining monitoree hosts of the plurality of hosts that are being monitored by the local host; sending a message to each of the monitor hosts identifying a value of the round counter; forwarding a first set of heartbeat messages from previous monitoree hosts to the monitor hosts; attempting to receive messages from the monitoree hosts; determining whether any messages were not received from the monitoree hosts; and in response to determining that one or more messages were not received from the monitoree hosts, generating an alert.

IPC Classes  ?

• H04L 9/40 - Network security protocols
• G06F 7/58 - Random or pseudo-random number generators
• G06F 9/54 - Interprogram communication
• G06F 21/60 - Protecting data
• G06F 21/54 - Monitoring users, programs or devices to maintain the integrity of platforms, e.g. of processors, firmware or operating systems during program execution, e.g. stack integrity, buffer overflow or preventing unwanted data erasure by adding security routines or objects to programs

Abstract

A device for mechanical securement to hard tissue of a subject, the hard tissue having an end surface defining a direction of curvature such that over at least a portion of the surface, a total curvature of at least 180 degrees is defined, the device comprising a body portion comprising at least four contact points, three contact points of the four contact point span over 180 degrees of total curvature of the end surface in a plane defined by the three contact points, and a fourth contact point outside the plane, the four contact points providing mechanical securement of the body portion to the hard tissue.

IPC Classes  ?

• A61F 2/32 - Joints for the hip

Abstract

The present disclosure provides systems, methods, and compositions for modifying a target nucleic acid. Particularly, the present invention relates to a polypeptide comprising a single subunit of a reverse transcriptase and a sequence-specific nuclease for use in prime-editing modification of a nucleic acid.

IPC Classes  ?

• C07K 14/155 - Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
• C07K 14/195 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/22 - Ribonucleases
• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

Abstract

A method of treating a condition in a subject by improving the immune response of the subject comprising first determining the level of TCF1 in the subject to identify the subject as having an anti-PD-1 responder phenotype or an anti-PD-1 non-responder phenotype, then administering an anti-PD-1 treatment to a subject having an anti-PD-1 responder phenotype or a metabolic inhibitor prior to ant-PD-1 treatment to a subject having an anti-PD-1 non-responder phenotype.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61K 31/52 - Purines, e.g. adenine
• A61P 37/02 - Immunomodulators

Abstract

A bioengineered human tissue platform that allows quantitative studies of the effects of radiation, and cryoinjury on engineered cardiac tissue and engineered bone marrow.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12M 1/16 - Apparatus for enzymology or microbiology containing, or adapted to contain, solid media
• C12M 1/18 - Multiple fields or compartments
• C12M 3/02 - Tissue, human, animal or plant cell, or virus culture apparatus with means providing suspensions
• C12M 3/08 - Apparatus for tissue disaggregation
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
• G01N 1/28 - Preparing specimens for investigation
• G01N 21/00 - Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light

Abstract

Described are lipopeptides that inhibit coronavirus fusion to a host cell. Thus a therapeutic for treating or preventing the common cold is described along with methods of inhibiting and/or treating an alphacoronavirus infection. The lipopeptides comprise a peptide unit comprising an amino acid sequence having a high degree of sequence identity to a sequence from the C-terminal heptad repeat of a betacoronavirus S protein, such as that of SARS-CoV-2.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

A system combining programmable bacteria cells that produce one or more antigens and optionally one or more cytokines and CAR-T cells that recognize and respond to at least one of the antigens to elicit an immune response against tumors and treat hyperproliferative disorders.

IPC Classes  ?

• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61K 35/74 - Bacteria
• C12N 1/20 - Bacteria; Culture media therefor
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA

Abstract

The present disclosure provides compositions and methods of treating motor neuron diseases, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). A modulator of a heat shock protein, such as an Hsp70 family member protein, may be used in the present method. Alternatively, a mutant heat shock protein may be used.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 35/761 - Adenovirus
• A61K 38/46 - Hydrolases (3)
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The disclosed matter provides systems and methods for encoding an assembly of three-dimensional (3D) hierarchically ordered nanoparticle architectures through chromatic bonds. Through identification of the repeating mesovoxels including chromatic bonds and voxels, the presented disclose matter can allow for encoding the 3D architectures by using symmetries of mesovoxel, enable a compression of the information amount required for encoding.

IPC Classes  ?

• G16B 15/10 - Nucleic acid folding
• G01N 23/201 - Measuring small-angle scattering, e.g. small angle X-ray scattering [SAXS]
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

Disclosed are devices, systems, apparatus, methods, products, and other implementations, including a method comprising obtaining, by a device, a combined sound signal for signals combined from multiple sound sources in an area in which a person is located, and applying, by the device, speech-separation processing (e.g., deep attractor network (DAN) processing, online DAN processing, LSTM-TasNet processing, Conv-TasNet processing), to the combined sound signal from the multiple sound sources to derive a plurality of separated signals that each contains signals corresponding to different groups of the multiple sound sources. The method further includes obtaining, by the device, neural signals for the person, the neural signals being indicative of one or more of the multiple sound sources the person is attentive to, and selecting one of the plurality of separated signals based on the obtained neural signals. The selected signal may then be processed (amplified, attenuated).

IPC Classes  ?

• G10L 25/30 - Speech or voice analysis techniques not restricted to a single one of groups characterised by the analysis technique using neural networks
• G10L 17/26 - Recognition of special voice characteristics, e.g. for use in lie detectors; Recognition of animal voices

Abstract

Devices for radiative cooling and optical waveguiding are provided, wherein the devices comprise a fabric including one or more fibers extending for a length in a longitudinal direction and a plurality of void structures positioned within each of the one or more fibers and extended over the length of each of the one or more fibers. Each of the plurality of void structures is configured to scatter at least a portion of an electromagnetic radiation received thereon to thereby radiatively cool the object.

IPC Classes  ?

• F28F 13/00 - Arrangements for modifying heat transfer, e.g. increasing, decreasing
• D01D 5/06 - Wet spinning methods
• D01D 5/16 - Stretch-spinning methods using rollers, or like mechanical devices, e.g. snubbing pins
• D01D 5/247 - Discontinuous hollow structure or microporous structure
• D01F 1/04 - Pigments
• D01F 2/00 - Monocomponent artificial filaments or the like of cellulose or cellulose derivatives; Manufacture thereof
• D01F 4/02 - Monocomponent artificial filaments or the like of proteins; Manufacture thereof from fibroin
• D01F 6/12 - Monocomponent man-made filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polymers of halogenated hydrocarbons from polymers of fluorinated hydrocarbons
• G02B 6/10 - Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• D01D 1/10 - Filtering or de-aerating the spinning solution or melt
• D06M 11/00 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
• D01D 1/06 - Feeding liquid to the spinning head
• D01F 1/06 - Dyes
• D01F 1/10 - Other agents for modifying properties

Abstract

Provided herein are methods, compositions, systems and kits for testing immune responses, safety, and efficacy of vaccines. In particular, the methods, compositions, systems and kits of the present invention test immune responses, duration of the immune responses, dose responses and age dependencies in cellular components of lymph nodes, other lymphoid tissues, mucosal tissues, barrier tissues, intestinal tissues, pulmonary tissues, and other solid tissues to vaccines after exposure in cell culture and tissue slices.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C12N 5/078 - Cells from blood or from the immune system
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• C12Q 1/6804 - Nucleic acid analysis using immunogens

Abstract

The subject matter described here relates to an enhancer specific to a subset of cholinergic neurons, that can control gene expression in a highly neuron-specific manner, wherein the enhancer is compatible with AAVs packaging and can induce gene expression or knockdown in cholinergic neurons in both post-natal and adult subjects.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 38/18 - Growth factors; Growth regulators
• C12N 15/864 - Parvoviral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

The system includes electrolyzers to generate acidic and alkaline effluent streams from saltwater. The electrolyzer include stacked pairs of porous anodes and cathodes that define feed channels into which reactants, e.g., hydrogen and brine, can be pumped to undergo an oxidation-reduction reaction. The porous cathode carries out the HER to generate H2, which floats upwards to the porous anode, where it is oxidized through the HOR. The reaction can thus progress in a self-maintaining manner. The HER creates an alkaline product stream with increased basicity, and the HOR an acidic product stream with increased acidity, compared to the inlet stream. Streams are pumped through the porous electrodes and the electrolyzer to sweep effluent through separate channels before they can combine. The alkaline product stream can have an alkalinity sufficient to drive metal ion precipitation in raw saltwater prior to feeding to the electrolyzer to reduce fouling/degradation of electrolyzer electrodes.

IPC Classes  ?

• C25B 9/70 - Assemblies comprising two or more cells
• C25B 11/031 - Porous electrodes
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• C25B 1/26 - Chlorine; Compounds thereof
• C25B 15/08 - Supplying or removing reactants or electrolytes; Regeneration of electrolytes

Abstract

Anti-annexin A1 antibodies are provided and methods of treating FAP and cancer using Anti-annexin A1 antibodies, antibody fragments or fusion proteins, including bispecific antibodies targeting two different annexin A1 epitopes, are also provided.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The subject matter described herein relates to potent monoclonal and bispecific antibodies capable of neutralizing a SARS-CoV-2 viruses and methods of generating the antibodies.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Disclosed herein is a kit for detecting or quantifying a SARS-CoV-2 nucleocapsid phosphoprotein, including a first antibody, wherein a variable heavy chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 11, 13, 15, 17, 19, and 21, and a variable light chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 12, 14, 16, 18, 20, and 22; and a second antibody, wherein a variable heavy chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 9 and 13, and a variable light chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 14.

IPC Classes  ?

• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The present disclosure relates to methods and compositions for increasing or extending lifespan and/or healthspan and/or delaying aging using agents which mimic the effects of time-restricted feeding and/or activate or enhance circadian-regulated autophagy. In particular, the present disclosure relates to increasing certain proteins including UNC-51-like kinase (ULK1), adenosine monophosphate protein kinase (AMPK) and microtubule-associated protein, light chain 3 (LC3), and decreasing other certain proteins including ribosomal protein S6 kinase beta-1 (S6K) protein in order to increase lifespan and/or healthspan and delay aging.

IPC Classes  ?

• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/18 - Sulfonamides
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin

Abstract

The invention described relates to the newly discovered ability of tumor internalizing arginylglycylaspartic acid (iRGD) peptides to alter the immune cell landscape in pancreatic ductal adenocarcinoma (PDAC) and other cancers. The iRGD peptides sensitize the cancer to immune checkpoint inhibitors, for example anti-PD-L1, anti-PD-L1, anti-PD-1, and anti-CTLA4 monoclonal antibodies to specifically deplete Tregs within the tumor, resulting in expansion of intratumoral CD8+ T cells (effector cells). This provides methods of treating cancers such as PDAC, preferably in synergistic combination with chemotherapy and immunotherapy, which leads to reduced tumor burden and prolonged survival.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

An energy storage system comprises a plurality of electrochemical cells. The electrochemical cells include a pair of electrodes including an anode and a cathode. An electrolyte in communication with the pair of electrodes. A flow shaping baffle is situated between the pair of electrodes. The flow shaping baffle includes a plurality of channels extending from a first end proximate the cathode to a second end proximate the anode along an axis substantially perpendicular to the electrodes. The first end has a first diameter and the second end has a second diameter. The first diameter is greater than the second diameter. The disclosed energy storage system does not require expensive pumps or ion exchange membranes and can operate efficiently over a long service life.

IPC Classes  ?

• H01M 10/36 - Accumulators not provided for in groups
• H01M 12/08 - Hybrid cells; Manufacture thereof composed of a half-cell of a fuel-cell type and a half-cell of the secondary-cell type
• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells
• H01M 8/0258 - Collectors; Separators, e.g. bipolar separators; Interconnectors characterised by the configuration of channels, e.g. by the flow field of the reactant or coolant

Abstract

A quantitative gait training and/or analysis system includes one or more footwear modules that may include a piezoresistive sensor, an inertial sensor and an independent logic unit. The footwear module functions to permit the extraction of gait kinematics and evaluation thereof in real time, or data may be stored for later reduction and analysis. Embodiments relating to calibration-based estimation of kinematic gait parameters are described, as well as biofeedback embodiments useful in training runners to maintain a time-varying target velocity or pace.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/103 - Measuring devices for testing the shape, pattern, size or movement of the body or parts thereof, for diagnostic purposes
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons

Abstract

This invention provides methods for detecting viruses, viral antigens, viral antibodies, and other antigens and antibodies using single molecule electronic nanopores and polymer tags.

IPC Classes  ?

• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/537 - Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody

Abstract

In one aspect the present invention is directed to mutant Neutrophil gelatinase-associated lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals

Abstract

Exemplary apparatus and method can be provided for use with ultrasound imaging. The apparatus can include at least one implantable device which is configured to communicate with an ultrasound imaging system, be located by the ultrasound imaging system using ultrasound signals generated thereby to generate a location of the implantable device(s), and transmit data to the ultrasound imaging system from the location of the implantable device(s) that was located by the ultrasound imaging system. Further, it is possible to implant, into a structure, at least one device which is responsive to ultrasound signals generated by the ultrasound imaging system, locale the device(s) within the structure by the ultrasound imaging system using the ultrasound signals to generate a location of the device(s) within the structure, and transmit data to the ultrasound imaging system from the location of the device(s) that was located by the ultrasound imaging system.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• H04B 11/00 - Transmission systems employing ultrasonic, sonic or infrasonic waves
• H02J 50/10 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
• A61N 7/00 - Ultrasound therapy

Abstract

The disclosure provides FOXO1 inhibitors having beneficial properties such as selectivity and metabolic stability. FOXO1 inhibitors are useful in the treatment of diabetes.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond

Abstract

Disclosed herein are methods for detecting methylation in cell-free polynucleotides and methods for detecting the presence of cancer in a subject.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/686 - Polymerase chain reaction [PCR]
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present disclosure provides for a pharmaceutical composition comprising ubiquinone-5 (UB5) and method of use thereof. The present disclosure relates to ubiquinone-5 used as an anesthetic, sedative agent, hypnotic agent, or combination thereof.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 9/107 - Emulsions
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 23/00 - Anaesthetics

Abstract

Disclosed are methods, systems, devices, and other implementations, including a voltage converter system that includes two or more Active Half Bridge (AHB) converter circuits, each of the two or more AHB converter circuits connected to one or more windings of a transformer, with each AHB converter circuit including one or more switches and one or more energy storage devices. The voltage converter system further includes one or more controllers to control electrical behavior of the two or more AHB converter circuits according to normalized switching functions representing the switching states of the switches of the two or more AHB converter circuits.

IPC Classes  ?

• H02M 3/24 - Conversion of dc power input into dc power output with intermediate conversion into ac by static converters
• H02M 3/28 - Conversion of dc power input into dc power output with intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate ac
• H02M 3/325 - Conversion of dc power input into dc power output with intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate ac using devices of a triode or a transistor type requiring continuous application of a control signal
• H02M 3/335 - Conversion of dc power input into dc power output with intermediate conversion into ac by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate ac using devices of a triode or a transistor type requiring continuous application of a control signal using semiconductor devices only
• H02M 1/00 - APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF - Details of apparatus for conversion
• H02M 1/08 - Circuits specially adapted for the generation of control voltages for semiconductor devices incorporated in static converters
• H02M 1/084 - Circuits specially adapted for the generation of control voltages for semiconductor devices incorporated in static converters using a control circuit common to several phases of a multi-phase system
• H02M 1/088 - Circuits specially adapted for the generation of control voltages for semiconductor devices incorporated in static converters for the simultaneous control of series or parallel connected semiconductor devices

Abstract

This disclosure to the methods for nucleic acid modification, gene targeting, and gene tagging comprising an engineered Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-associated transposon (CAST) system with a donor DNA comprising at least one engineered transposon end sequence and/or at least one integration co-factor protein. More particularly, the present disclosure provides systems comprising: an engineered CAST system or one or more nucleic acids encoding the engineered CAST system, wherein the CAST system comprises at least one or all of: i) at least one Cas protein, ii) one or more transposon-associated proteins, iii) at least one guide RNA (gRNA) complementary to at least a portion of a target nucleic acid sequence; and a donor nucleic acid comprising a cargo nucleic acid sequence flanked by at least one engineered transposon end sequence and/or at least one integration co-factor protein, or a nucleic acid encoding thereof.

IPC Classes  ?

• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

StreptococcusStreptococcus (PANDAS). Also provided are diagnostic methods for PANS (such as PANDAS) where the methods assay the levels of one or more cytokines, chemokines and/or growth factors in a sample taken from a subject.

IPC Classes  ?

• G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants